Table 2. Putative positively selective regions

Unknown epitopes identified only in the HIV-negative group are shown in bold.

Region	PS value*	HCV with HIV	HCV without HIV		
E1	PS>1.0	366–368	**192–195**,	**203–205**,	212–215,
			223–229,	234–237,	**245–247**,
			255–257,	295–299,	**346–349**
			353–358,	**359–361**	
E2	PS>1.0	383–412, 414–418, 434–438	382–410,	418–420,	432–436,
			443–446,	463–465,	**480–482**,
			486–488	496–500	

*PS (positive selection) = $(d_N+0.5)/(d_S+0.5)$.

with HIV and HCV (Braitstein *et al.*, 2004; Graham *et al.*, 2001). Another cohort study of HIV/HCV-coinfected patients also indicated association of low CD4 cell count, alcohol consumption rate and age at HIV/HCV coinfection with acceleration of the liver fibrosis (Benhamou *et al.*, 1999). The increased HCV replication in the HIV/HCV-coinfected patients would induce an intermediate immune response that is large enough to induce hepatic cell destruction and fibrosis but not enough to eradicate the virus from its reservoirs (Lai *et al.*, 2003; Poynard *et al.*, 2003).

In the present study, the genetic diversity of HCV was higher in the HIV-positive group compared with the HIV-negative group, which could be associated with either or both higher rate of HCV replication and HIV-associated immunosuppression, leading to less selective pressure on HCV in the HIV-positive group. The increased HCV replication by immune dysregulation in the HIV/HCV-coinfected patients might damage liver cells through apoptosis and other means such as cytokine disruption as reported previously (Puoti *et al.*, 2001). Although several



Fig. 4. Comparative histograms of the E1 and E2 regions of the HCV clones from HIV-positive (HIV+) and -negative (HIV−) patients. *y*-axis indicates $(d_N+0.5)/(d_S+0.5)$ ratio, columns exceeding value 1.0 represent the putative positively selective regions. Regions outside of any known CTL epitopes are indicated by asterisks and probably indicate unknown epitopes. *x*-axis indicates the schematic position in the HCV genes: C, core; HVR1, hypervariable region.

studies showed that HCV diversity decreases with the degree of HIV-related immunosuppression (Babik & Holodniy, 2003; Mao *et al.*, 2001; Martell *et al.*, 1992; Qin *et al.*, 2005; Roque-Afonso *et al.*, 2002; Toyoda *et al.*, 1997), this might be associated with the different parameters assessed for the genetic diversity; the conclusions in most previous studies were made by analysing total numbers of HCV clones and overall genetic distances at the amino acid level.

To assess the discrepancy with our results by coalescence-based estimation, we further examined the role of HCV-targeted immune pressure. The HCV nucleotide substitution pattern was compared between subjects with intact immune system versus those with HIV-associated immunosupression using a recently designed approach. Previous reports had used the mean of pairwise synonymous and non-synonymous distances within isolates (Ray *et al.*, 2000; Blackard *et al.*, 2004). Since most isolates do not have an independent evolutionary process, the mean may not represent overall genetic diversity of the heterogeneous viral population. To examine the non-redundant evolutionary process, recent methods have inferred the evolutionary process throughout the phylogenetic tree (Sheridan *et al.*, 2004; Suzuki & Gojobori, 2001; Hanada *et al.*, 2006). In the present study, we have applied a new approach to examine selection of HCV affected by HIV. The approach supported the theory that the diversified population of HIV-positive patients is due to less selective pressure and allows identification of specific regions indicating the presence of positive selection in HIV-negative patients compared with HIV-positive patients with immunosuppression. Although these positively selective segments, which were observed only in the HIV-negative group, might have relatively weak antigenicity, most of them were located inside potential immunogenic targets and others might be somewhat new antigen-recognition regions associated with HCV-specific immune responses. Interestingly, no influence by HIV coinfection was observed in the HVR1, which contains sequence-specific immunological B-cell epitopes that induce the production of antibodies restricted to the specific viral isolate (Kato *et al.*, 1993), indicating that the positively selected segments regardless of HIV infection should have strong antigenic epitopes. Taken together, our findings indicate that defenceless HCV clones that are extinct in usual conditions can survive in HIV-positive patients because of less immune pressure leading to HIV infection. Consequently, the genetic diversity of HCV will be greater in HIV-positive patients. In fact, the diversity of both synonymous and non-synonymous substitutions was larger in HIV-positive patients than HIV-negative patients (data not shown).

One limitation of the present study is the general lack of functional immunological data. In this study, HCV-specific CD4 ELISPOT responses were not detected in all subjects and CD8 cell counts were not measured. Therefore, we chose to use HIV load and CD4 cell counts as surrogate markers of immune suppression. Further investigations of HCV diversity in conjunction with HCV-specific cellular responses will be required when more-sensitive immunological assays are available. Another potential limitation of the study is that only two time points were sampled for each individual. However, as we inferred the evolutionary process based on the phylogenetic tree constructed using the number of clones that were isolated through the long period of follow-up (more than 6 years), we believe that the genetic diversity of the heterogeneous viral population may represent an actual evolutionary process.

In conclusion, HIV-positive patients have more diversified HCV populations than HIV-negative patients, possibly because of reduction of selective pressure from the immune system. The positively selective regions determined in this study might be antigen-recognition regions associated with HCV-specific immune responses.

ACKNOWLEDGEMENTS

Financial support: the work was supported by a grant-in-aid from the Ministry of Health, Labour and Welfare of Japan and from the Ministry of Education, Culture, Science, Sports of Japan and Japan Science and Technology Agency. Potential conflicts of interest: we do not have any commercial or other association that may pose a conflict of interest.

REFERENCES

Babik, J. M. & Holodniy, M. (2003). Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients. *J Virol* **77**, 1940–1950.

Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P. & other authors (1999). Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. *Hepatology* **30**, 1054–1058.

Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R. & Snydman, D. R. (2001). Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. *Clin Infect Dis* **32**, 492–497.

Blackard, J. T., Yang, Y., Bordoni, P., Sherman, K. E., Chung, R. T. & AIDS Clinical Trials Group 383 Study Team (2004). Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy. *J Infect Dis* **189**, 1472–1481.

Braitstein, P., Palepu, A., Dieterich, D., Benhamou, Y. & Montaner, J. S. (2004). Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C. *AIDS* **18**, 2221–2234.

Devereux, H. L., Brown, D., Dusheiko, G. M., Emery, V. C. & Lee, C. A. (1997). Long-term evolution of the 5′UTR and a region of NS4 containing a CTL epitope of hepatitis C virus in two haemophilic patients. *J Gen Virol* **78**, 583–590.

Eyster, M. E., Fried, M. W., Di Bisceglie, A. M. & Goedert, J. J. (1994). Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. *Blood* **84**, 1020–1023.

Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J. C., Strazzera, A., Chien, D. Y., Munoz, S. J. & other authors (2000).

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science* **288**, 339–344.

Farci, P., Strazzera, R., Alter, H. J., Farci, S., Degioannis, D., Coiana, A., Peddis, G., Usai, F., Serra, G. & other authors (2002). Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. *Proc Natl Acad Sci U S A* **99**, 3081–3086.

Goedert, J. J., Eyster, M. E., Lederman, M. M., Mandalaki, T., De Moerloose, P., White, G. C., II, Angiolillo, A. L., Luban, N. L., Sherman, K. E. & other authors (2002). End-stage liver disease in persons with hemophilia and transfusion-associated infections. *Blood* **100**, 1584–1589.

Graham, C. S., Baden, L. R., Yu, E., Mrus, J. M., Carnie, J., Heeren, T. & Koziel, M. J. (2001). Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis* **33**, 562–569.

Hanada, K., Gojobori, T. & Li, W. H. (2006). Radical amino acid change versus positive selection in the evolution of viral envelope proteins. *Gene* **385**, 83–88.

Hanada, K., Tanaka, Y., Mizokami, M., Gojobori, T. & Alter, H. J. (2006). A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation. *Virology* **361**, 27–33.

Kato, N., Sekiya, H., Ootsuyama, Y., Nakazawa, T., Hijikata, M., Ohkoshi, S. & Shimotohno, K. (1993). Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. *J Virol* **67**, 3923–3930.

Kumar, S., Tamura, K., Jakobsen, I. B. & Nei, M. (2001). MEGA2: Molecular Evolutionary Genetics Analysis software. *Bioinformatics* **17**, 1244–1245.

Lai, C. L., Ratziu, V., Yuen, M. F. & Poynard, T. (2003). Viral hepatitis B. *Lancet* **362**, 2089–2094.

Lyra, A. C., Fan, X., Lang, D. M., Yusim, K., Ramrakhiani, S., Brunt, E. M., Korber, B., Perelson, A. S. & Di Bisceglie, A. M. (2002). Evolution of hepatitis C viral quasispecies after liver transplantation. *Gastroenterology* **123**, 1485–1493.

Mao, Q., Ray, S. C., Laeyendecker, O., Ticehurst, J. R., Strathdee, S. A., Vlahov, D. & Thomas, D. L. (2001). Human immunodeficiency virus seroconversion and evolution of the hepatitis C virus quasispecies. *J Virol* **75**, 3259–3267.

Martell, M., Esteban, J. I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J. & Gomez, J. (1992). Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. *J Virol* **66**, 3225–3229.

Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J. & Perelson, A. S. (1998). Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. *Science* **282**, 103–107.

Ohno, T., Mizokami, M., Wu, R. R., Saleh, M. G., Ohba, K., Orito, E., Mukaide, M., Williams, R. & Lau, J. Y. (1997). New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. *J Clin Microbiol* **35**, 201–207.

Pawlotsky, J. M., Germanidis, G., Frainais, P. O., Bouvier, M., Soulier, A., Pellerin, M. & Dhumeaux, D. (1999). Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. *J Virol* **73**, 6490–6499.

Poynard, T., Yuen, M. F., Ratziu, V. & Lai, C. L. (2003). Viral hepatitis C. *Lancet* **362**, 2095–2100.

Puoti, M., Bonacini, M., Spinetti, A., Putzolu, V., Govindarajan, S., Zaltron, S., Favret, M., Callea, F., Gargiulo, F. & other authors (2001). Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. *J Infect Dis* **183**, 134–137.

Pybus, O. G. & Rambaut, A. (2002). GENIE: estimating demographic history from molecular phylogenies. *Bioinformatics* **18**, 1404–1405.

Pybus, O. G., Charleston, M. A., Gupta, S., Rambaut, A., Holmes, E. C. & Harvey, P. H. (2001). The epidemic behavior of the hepatitis C virus. *Science* **292**, 2323–2325.

Qin, H., Shire, N. J., Keenan, E. D., Rouster, S. D., Eyster, M. E., Goedert, J. J., Koziel, M. J. & Sherman, K. E. (2005). HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. *Blood* **105**, 533–541.

Rambaut, A. (2000). Estimating the rate of molecular evolution: incorporating non-contemporaneous sequences into maximum likelihood phylogenies. *Bioinformatics* **16**, 395–399.

Ray, S. C., Mao, Q., Lanford, R. E., Bassett, S., Laeyendecker, O., Wang, Y. M. & Thomas, D. L. (2000). Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees. *J Virol* **74**, 3058–3066.

Roque-Afonso, A. M., Robain, M., Simoneau, D., Rodriguez-Mathieu, P., Gigou, M., Meyer, L. & Dussaix, E. (2002). Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus. *J Infect Dis* **185**, 728–733.

Sheridan, I., Pybus, O. G., Holmes, E. C. & Klenerman, P. (2004). High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. *J Virol* **78**, 3447–3454.

Suzuki, Y. & Gojobori, T. (2001). Positively selected amino acid sites in the entire coding region of hepatitis C virus subtype 1b. *Gene* **276**, 83–87.

Tanaka, Y., Hanada, K., Mizokami, M., Yeo, A. E., Shih, J. W., Gojobori, T. & Alter, H. J. (2002). A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. *Proc Natl Acad Sci U S A* **99**, 15584–15589.

Toyoda, H., Fukuda, Y., Koyama, Y., Takamatsu, J., Saito, H. & Hayakawa, T. (1997). Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. *J Hepatol* **26**, 975–982.

Yang, Z., Kumar, S. & Nei, M. (1995). A new method of inference of ancestral nucleotide and amino acid sequences. *Genetics* **141**, 1641–1650.

Journal of Medical Virology 79:1113–1119 (2007)

Prediction of the Efficacy of Antiviral Therapy for Hepatitis C Virus Infection by an Ultrasensitive RT-PCR Assay

Ei Kinai,[1] Hideji Hanabusa,[2] and Shingo Kato[3]*

[1]*Department of Pediatrics, Keio University Hospital,, Shinjuku-ku, Tokyo, Japan*
[2]*Department of Haematology, Ogikubo Hospital, Suginami-ku, Tokyo, Japan*
[3]*Department of Microbiology and Immunology, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan*

The efficacy of interferon therapy for hepatitis C virus (HCV) infection improved remarkably. However, virologic relapse occurs in a substantial proportion of patients with virologic response (defined as an HCV RNA level below 50 IU/ml at the end-of-treatment). A highly sensitive RT-nested PCR assay capable of detecting almost a single copy of HCV RNA and a real-time RT-PCR assay to quantify HCV RNA down to 120 copies per ml were developed. The RT-nested PCR assay showed that 1 IU of HCV RNA is equivalent to 12.2 copies. For 28 patients with virologic response (12 relapsers and 16 sustained virologic responders), week-4 and end-of-treatment plasma samples were retested. At week 4, HCV RNA was detected by the RT-nested PCR and qualitative COBAS Amplicor HCV version 2.0 in 8/9 (89%) and 6/9 (67%) samples from relapsers, and in 4/16 (25%) and 2/16 (13%) samples from sustained virologic responders, respectively. End-of-treatment samples with HCV-negative by the qualitative COBAS Amplicor were positive by the present assay in 4/12 (25%) of relapsing patients and 0/16 (0%) of sustained virologic responders. The viral levels detected by the present assay in the Amplicor-negative samples were 3.5–17.3 copies/ml, which is below the detection limit of COBAS Amplicor. In conclusion, the highly sensitive RT-nested PCR assay can predict sustained virologic response at week 4 and virologic relapse at the end-of-treatment more accurately than COBAS Amplicor, suggesting its usefulness in monitoring antiviral therapy for HCV infection. ***J. Med. Virol. 79:1113–1119, 2007.*** © 2007 Wiley-Liss, Inc.

KEY WORDS: hepatitis C virus; ultrasensitive RT-PCR; accurate prediction; residual HCV RNA

INTRODUCTION

Hepatitis C Virus (HCV) chronically infects over 170 million people worldwide. After acute infection, approximately 15% to 25% of infected individuals overcome the virus with resolution of the infection, while the remainders become chronically infected. Of individuals with chronic infection, 10% to 20% progress and thereafter 1% to 5% develop hepatocellular carcinoma [Cohen, 1999]. In Japan, the number of HCV-infected patients is estimated to be 3 million in a population of 120 million. It should be noted that over 90% of hemophilia patients had been infected with HCV and about 40% had been co-infected with human immunodeficiency virus from contaminated blood products in the early 1980s. They are now facing an increasing risk of developing end-stage liver disease.

Recently, treatment for chronic hepatitis C has made remarkable progress. Current protocols of combination therapy of peginterferon plus ribavirin have achieved high rates (40–63%) of sustained virologic response [Manns et al., 2001; Fried et al., 2002; Hadziyannis et al., 2004; Torriani et al., 2004], defined as a serum HCV RNA < 50 IU/ml at week 24 after the end-of-treatment. Since it was reported that patients who did not achieve an early virologic response (EVR), defined as a serum HCV RNA < 50 IU/ml at week 12, did not respond to further therapy [Davis et al., 2003], the consensus guidelines have recommended that therapy be discontinued for patients who did not achieve EVR [European Association for the Study of the Liver, 1999; National Institutes of Health Consensus Development Conference, 2002; Strader et al., 2004]. Moreover, to avoid side effects and save treatment costs, early identification of nonresponse or relapse is increasingly required. Although rapid virologic response, defined as a serum HCV RNA < 50 IU/ml at week 4, was reported to be highly associated with sustained virologic response, virologic relapse occurred at various rates (9–27%)

*Correspondence to: Shingo Kato, Department of Microbiology and Immunology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
E-mail: skato@sc.itc.keio.ac.jp

Accepted 24 April 2007
DOI 10.1002/jmv.20908
Published online in Wiley InterScience (www.interscience.wiley.com)

© 2007 WILEY-LISS, INC.

WILEY InterScience
DISCOVER SOMETHING GREAT

among patients who achieved rapid virologic response [Jensen et al., 2006]. This may be explained by the fact that the detection limit of 50 IU/ml is not low enough to identify the patients with strong early virologic suppression that leads to sustained virologic response.

Several studies using highly sensitive HCV assays have shown that virologic relapse can occur in patients with a low level of residual HCV RNA at the end-of-treatment, which cannot be detected by COBAS Amplicor HCV version 2.0 (Roche Molecular diagnostics, Pleasanton, CA) [Sarrazin et al., 2001; Watkins-Riedel et al., 2004; Desombere et al., 2005; Gerotto et al., 2006]. However, early virologic assessment has not been fully evaluated with such highly sensitive assays. To evaluate accurately the relationships between EVR and sustained virologic response, and between the residual HCV RNA at the end-of-treatment and virologic relapse, a highly sensitive reverse transcription (RT)-nested PCR assay that detect almost a single copy of HCV RNA and a real-time RT-PCR assay with a wide quantitation range were developed. These techniques were used to retest plasma samples from patients with relapse or sustained virologic response who had virologic responses at the end-of-treatment.

MATERIALS AND METHODS

Patients and Samples

Plasma samples were collected from 28 patients who had been treated with interferon therapy at Ogikubo Hospital (Tokyo, Japan) and achieved virologic responses at the end-of-treatment; 12 relapsers and 16 sustained virologic responders. All patients were male hemophiliac patients and had been infected with HCV through contaminated blood products. The characteristics of patients are shown in Table I. There were no significant differences in age, sex, HIV-1 co-infection or alanine aminotransferase levels between relapser and sustained virologic responders groups. Although the patients with genotype 1 infection appeared to have a higher rate of relapse, a statistical difference was not obtained ($P = 0.13$). All plasma samples were stored at $-60°C$ until analysis.

RNA Extraction

Total RNA was extracted from 500 μl of plasma using a QIAamp UltraSens Virus Kit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer's recommendations with some modifications. Briefly, plasma was diluted with 500 μl of phosphate buffered saline and centrifuged at 18,000 rpm (35,000*g*) for 60 min. Most of the supernatant was discarded and the residual 30 μl and precipitate were resuspended with 300 μl of Buffer AR containing 5.6 μl of carrier RNA preheated at 60°C. The mixture was incubated for 10 min at 60°C using a mixing incubator. Thereafter, RNA was purified as recommended.

Reverese Transcription-Nested PCR

Primers. Reverse transcription (RT)-nested PCR was performed using two sets of primers targeting a region of the 5′ untranslated region of HCV. Reverse transcription (RT) was carried out with primer KC12, 5′-CTCGCAAGCACCCTATCAGGCAG-3′ (nucleotides (nt) 276–299, identical to primer KY78 designed by Roche Molecular Systems) [Young et al., 1993]. The primer pair for the first-round PCR consisted of forward primer KC11, 5′-CTCCCCTGTGAGGAACTACTGTCT-3′ (nt 24–51), and reverse primer KC12. The primer pair for the second-round PCR consisted of forward primer KC13, 5′-TCCCGGGAGAGCCATAGTG-3′ (nt 115–133) and reverse primer KC14, 5′-TCCAAGAAAGGACCC-3′ (nt 176–196).

RT-nested PCR. RT was carried out in a 20-μl solution of PCR Buffer II (10 mM Tris–HCl, 50 mM KCl), 3 mM $MgCl_2$, 10 mM of DTT, 0.5 mM of each dNTP, 0.5 μM of RT primer (KC12), 0.5 U of RNase inhibitor (Promega, Madison, WI), and 2.5 U of SuperScript III (Invitrogen, Carlsbad, CA). The mixture was incubated for 5 min at 60°C, 5 min at 55°C, 5 min at 50°C, and then 5 min at 45°C. A GeneAmp PCR system 9700 thermocycler and thin-walled MicroAmp reaction tubes (Applied Biosystems, Foster City, CA) were employed for RT and PCR. The first-round PCR was carried out using the whole RT product in a final volume of 50 μl containing 1× PCR Buffer II, 2.5 mM $MgCl_2$, 200 μM

TABLE I. Patient Characteristics

Category	Virologic relapsers	Sustained virologic responders
Number of cases	12	16
Age, median (in years) (range)	35 (24–69)	32 (20–66)
Sex, male/female	12/0	16/0
Genotype[a]		
1	5 (42%)	0 (0%)
2	2 (17%)	2 (40%)
3	5 (42%)	2 (40%)
4	0 (0%)	1 (20%)
HIV co-infection		
HIV positive	6 (50%)	6 (38%)
HIV negative	6 (50%)	10 (62%)
ALT level, median (in U/L) (range)[b]	115 (29–264)	120 (59–708)

[a]Of 16 cases with sustained virologic response, genotype was determined in five cases.
[b]ALT, Alanine aminotransferase.

each dNTP, 1 μM KC11 and KC12 primers, and 1.25 U of AmpliTaq DNA polymerase. The mixture was incubated for 2 min at 97°C to facilitate denaturation, then PCR amplification was performed with 5 cycles of 5 sec at 97°C (denaturation), 15 sec at 48°C (annealing), and 15 sec at 60°C (extension), 25 cycles of 5 sec at 94°C and 15 sec at 60°C, and a final extension step of 5 min at 72°C. One microliter of the first-round PCR product was applied to the second-round PCR in a 50-μl solution containing the same components as the first-round PCR except for primers KC13 and KC14 instead of KC11 and KC12. PCR amplification was performed with preincubation of 2 min at 94°C, 5 cycles of 5 sec at 94°C, 15 sec at 48°C, and 15 sec at 60°C, 25 cycles of 5 sec at 94°C and 15 sec at 60°C, and a final extension step of 5 min at 72°C. The final PCR product was analyzed by electrophoresis in 2% agarose gel containing 0.5 μg/ml ethidium bromide.

Evaluation of Extraction Efficiency

Extraction efficiency was evaluated by comparing the HCV RNA copy counts of seven samples (one sample of genotype 1a, two genotype 1b, one genotype 2a, one genotype 2b, one genotype 3a, and one genotype 4) determined by Poisson quantitation (described below) of HCV RNA in plasma and purified RNA obtained from plasma using the modified RNA extraction protocol.

Poisson quantitation of purified RNA. The HCV RNA concentration was determined by statistical analysis of the results of RT-nested PCR of the sample diluted to near endpoint. First, serial 10-fold dilutions of the extracted RNA solution were assayed with RT-nested PCR as described above. Then, the diluted solution that had conferred the second to last positive band was serially diluted twice and tested with RT-nested PCR. Finally, the RNA solution diluted at the ratio by which the last positive signal was given in a series of twofold dilutions was assayed in 20 replicates. Assuming that a single copy of HCV RNA is detectable, the HCV concentration can be calculated from the proportion of negative reactions (P_0) using the null class equation of the Poisson distribution [Simmonds et al., 1990]. The formula is HCV RNA concentration $= -\ln P_0 / V \times d$ (copies/μl), where V and d are the sample volume (μl) assayed and the dilution ratio, respectively. In these experiments, RNA Diluting Buffer (50% glycerol, 10 mM Tris–HCl, pH 8.0, 1 mM EDTA, 0.05% Sarkosyl, 10 μg/ml poly A) was used to ensure no loss of RNA during the dilution procedures. We call the above procedure "Poisson quantitation."

Direct poisson quantitation of plasma RNA. Sample plasma was diluted with Virus Lysis Buffer (50% glycerol, 10 mM Tris–HCl, pH 8.0, 1 mM EDTA, 0.05% Sarkosyl, 10 μg/ml poly A, 2 mM DTT, and 0.4 U/μl RNase inhibitor). Diluted samples were quantified by Poisson quantitation without RNA extraction. This method can quantify the absolute copy number of HCV RNA in plasma, since it is not affected by loss of RNA during the purification procedure. It was confirmed that contamination of less than 0.1 μl of plasma in one reaction did not affect quantitation of HCV RNA in this RT-PCR condition.

HCV RNA Real-Time RT-PCR

RT was carried out using a high-capacity cDNA Archive kit (Applied Biosystems) in a final volume of 10 μl containing 5 μl of RNA sample solution and 0.3 μM of KC12 primer. The RT reaction was carried out with a GeneAmp PCR system 9700 for 30 min at 48°C, followed by reverse transcriptase inactivation for 5 min at 95°C. The PCR reaction was carried out in a final volume of 50 μl containing 10 μl of the RT product, TaqMan buffer (Applied Biosystems), 5 mM $MgCl_2$, 400 μM dUTP, 200 μM dATP, dCTP, dGTP (each), 0.025 U/μl AmpliTaq Gold, 0.01 U/μl AmpErase UNG, 0.3 μM forward primer (KC13), and reverse primer (KC14). For signal detection, 0.1 μM MGB probe 5′-CTGCGGAACCGGTG-3′ (KCP) was used. The PCR amplification was performed using Sequence Detection Systems 7700 (Applied Biosystems). The temperature settings were: uracil-*N*-glycosylase incubation for 2 min at 50°C; AmpliTaq Gold activation for 10 min at 95°C; 40 cycles of 15 sec at 95°C; and 1 min at 60°C. Measurements of standard and unknown samples were done in triplicate. After amplification, real-time data acquisition and analysis were performed with the accompanying software. For the standard HCV RNA, we used an RNA solution purified from the plasma of one patient with genotype 1b, which is the most common genotype among Japanese patients and quantified by Poisson quantitation.

Detection and Quantitation of HCV RNA in Clinical Samples

From 28 HCV-infected patients who achieved a viral response with antiviral treatment (12 relapsers and 16 sustained virologic responders), 53 stored plasma samples at week 4 and at the end-of-treatment (9 week-4 samples and 12 end-of-treatment samples from relapsers, and 16 week-4 samples and 16 end-of-treatment samples from sustained virologic responders) were retested by the RT-nested PCR and real-time RT-PCR assays developed in this study. One tenth of the RNA purified from plasma samples as described above was subjected to in-house RT-nested PCR in 10 replicates. Plasma in which HCV RNA was detected in nine or more reactions was quantified by real-time RT-PCR, because a reliable HCV RNA value cannot be obtained for these samples by Poisson quantitation. The results of the RT-nested PCR and COBAS Amplicor HCV v2.0 assays were tested by Fisher's exact probability test with respect of the outcome.

RESULTS

Extraction Efficiency

The efficiency of HCV RNA extraction in the modified protocol of QIAamp UltraSens Virus kit was estimated by comparing the quantities of HCV RNA in seven plasma samples and in their extracted RNA, involving

six different HCV genotypes. The ratios ranged from 50% to 107% with a median of 89%.

Sensitivity of RT-Nested PCR

To evaluate the sensitivity of the RT-nested PCR, the World Health Organization international standard for HCV RNA (NIBSC code 96/798) was quantified by Poisson quantitation. In a total of 4 runs, HCV RNA was detected in 24 reactions of 34 replicates. This result showed that 1 IU was equivalent to 12.2 amplifiable copies (range based on SD, 9.9–15.3 copies).

Linearity, Reproducibility, and Genotype Reactivity of Real-Time RT-PCR

The data obtained for drawing the standard curves in the real-time RT-PCR assay were statistically analyzed to assess the precision within each run (intra-assay) and between runs (inter-assay). The standard curves were obtained with 10-fold dilutions of the RNA standard, ranging from 5 to 5,000 copies per reaction (equivalent to 120–120,000 copies/ml), and analyzed in triplicate in a total of four independent experiments. The results of the analysis are summarized in Table II. The standard deviation of the intra-assay on the basis of C_T values ranged from 0.05 to 0.74 cycles, even including samples with only 5 copies per reaction, and that of the inter-assay ranged from 0.70 to 1.42 cycles.

To overcome the variation of nucleotide sequences of 5′ untranslated region among HCV genotypes, we used the most conserved region for designing PCR primers. To evaluate the genotype reactivity of the real-time RT-PCR, obtained values of HCV RNA were compared with those determined by Poisson quantitation for HCV strains of various genotypes. There was very good linearity between the real-time RT-PCR and Poisson quantitation regardless of genotype (Fig. 1). The coefficient of variation ranged from 7.2% to 30.8% for all quantified points and all genotypes.

Detection and Quantitation of HCV RNA in Stored Plasma

From 28 patients who achieved virologic responses at the end-of-treatment, 53 plasma samples at week 4 or at the end-of-treatment were retested by the RT-nested PCR. The detection rates, statistical tests of week-4 and end-of-treatment samples, and the predictability of sustained virologic response by the undetectability of HCV RNA and relapse by the detection of HCV RNA are shown in Table III. In testing week-4 samples, the RT-nested PCR assay detected HCV RNA in 8 of 9 (89%) available samples from relapsers, and in 4 of 16 (25%) from sustained virologic responders ($P = 0.003$), whereas COBAS Amplicor detected 6/9 (67%) from relapsers and 2/16 (13%) from sustained virologic responders ($P = 0.01$). Among the 13 patients who were HCV RNA-negative at week 4 by the RT-nested PCR assay, 12 (92%) achieved sustained virologic response, compared to 14 of the 17 (82%) who were negative by COBAS Amplicor. In testing end-of-treatment samples, 4 of 12 (33%) Amplicor-negative samples from relapsers were HCV-positive by the RT-nested PCR assay, whereas 0 of 16 end-of-treatment samples from sustained virologic responders were HCV-positive ($P = 0.02$). Among the four patients who were HCV RNA-positive at the end-of-treatment by the RT-nested PCR assay, four (100%) had virologic relapse.

The viral load determined by Poisson quantitation in eight Amplicor-negative samples (six samples from relapsers and two samples from sustained virologic responders) were within 3.5–17.3 copies/ml (Table IV), which was below the detection limit of current highly sensitive assays such as transcription-mediated amplification.

DISCUSSION

This study demonstrates that an ultrasensitive HCV assay can identify both sustained virologic response and relapse in patients with high probabilities. As previously shown, the more sensitive the assay used for the quantitation of HCV RNA, the more predictive the measurements are of virologic relapse after discontinuation of therapy [Sarrazin et al., 2001; Desombere et al., 2005]. The currently developed highly sensitive HCV assay based on RT-nested PCR has an ability to detect almost a single copy of HCV RNA, which was achieved by a stepwise declining temperature in reverse transcription and a lower annealing temperature of 48°C for the first five PCR cycles. To assess the sensitivity of this assay, equivalency between the international unit and the amplifiable copy number of HCV RNA was determined using the WHO international standard. The international unit was first determined in 1998 based on a mean of measurements for the WHO international standard that were quantified by 22 multinational laboratories using various quantitation methods in 1998 [Saldanha et al., 1999], therefore, it is not yet clear how many HCV virions are equivalent to 1 IU.

TABLE II. C_T Values With RNA Dilutions for Standard Curve (Genotype 1b)

Copies/reaction	Experiment 1	Experiment 2	Experiment 3	Experiment 4	Inter-assay (std dev)
5,000	22.20 (0.05)	23.60 (0.23)	22.30 (0.12)	21.98 (0.15)	0.70
500	26.54 (0.28)	27.59 (0.35)	25.90 (0.21)	25.39 (0.12)	0.88
50	30.99 (0.21)	31.35 (0.48)	29.14 (0.16)	28.55 (0.11)	1.26
5	35.46 (0.74)	35.40 (0.64)	33.27 (0.60)	32.60 (0.28)	1.42

Serially diluted samples were analyzed in triplicate in each experiment. Good consistency (intra-assay) and reproducibility (inter-assay) of the real-time PCR are shown in this table.



Fig. 1. Linearity of yield with RNA dilutions isolated from genotype 1a, 1b, 2a, 2b, 3a, and 4 samples. A sample from each genotype was serially diluted, and quantified by real-time RT-PCR. Actual yield copy counts were obtained from 10-fold diluted RNA samples by real-time RT-PCR, and theoretical yield copy counts were obtained from the dilution based on Poisson quantification using our RT-nested PCR.

Previously, conversion factors of international unit and amplifiable copy were determined at 2.75 and 5.2 copies/IU by Puig et al. [2002] and Gorrin et al. [2003], respectively. The result of 12.2 copies/IU in this study, which was obtained by analyzing the Poisson distribution of clear positive reactions at endpoint dilution of the WHO international standard, was considerably higher than the previous values. Taken together with a high efficiency (89%) of extraction of HCV RNA from plasma, the present assay is considered to have the ability to detect almost a single copy of HCV RNA in plasma samples.

The present qualitative RT-nested PCR assay was compared with the COBAS Amplicor HCV version 2.0 with a lower detection limit of 50 IU/ml for 53 plasma samples from 28 patients receiving antiviral therapy that were collected at week 4 or the end-of-treatment. While COBAS Amplicor detected HCV RNA in 8 samples, the present assay detected HCV RNA in 16 samples (all of 8 Amplicor-positive samples and 8 of 45 Amplicor-negative samples), providing evidence that the assay is more sensitive for the detection of HCV RNA in clinical samples than COBAS Amplicor version 2.0. Furthermore, regarding prediction of relapse or sustained virologic response after treatment, the present assay is more predictive than COBAS Amplicor at week 4 ($P = 0.003$ vs. $P = 0.02$) as well as at the end-of-treatment ($P = 0.02$ vs. $P = 1$). It is most likely that this difference is explained by a lower detection limit of the present assay. As mentioned above, the RT-nested PCR assay is approaching the ability to detect a single copy of HCV RNA. Therefore, when a 0.5 ml plasma sample is used, the sensitivity of the assay can be calculated from the equation for the Poisson distribution as 5 copies/ml at 95% detection, which is lower than 50 IU/ml for COBAS Amplicor and 25–50 copies/ml for transcription-mediated amplification assay (VERSANT HCV RNA Qualitative Assay) [Sarrazin et al., 2001].

TABLE III. Comparison of the Detection Rates of HCV RNA by Our in-House RT-Nested PCR at Week 4 and the End-of-Treatment, and COBAS Amplicor HCV Version 2.0 at Week 4

	In-house RT-nested PCR			COBAS Amplicor HCV v2.0		
	Relapse	Sustained virologic response		Relapse	Sustained virologic response	
Week 4						
Positive	8	4	Relapse/total positive = 8/12 (67%)	6	2	Relapse/total positive = 6/8 (75%)
Negative	1	12	SVR/total negative = 12/13 (92%)	3	14	SVR/total negative = 14/17 (82%)
P-value	0.003			0.02		
End-of-treatment						
Positive	4	0	Relapse/total positive = 4/4 (100%)	0	0	Relapse/total positive = 12/0
Negative	8	16	SVR/total negative = 16/24 (67%)	12	16	SVR/total negative = 16/28 (57%)
P-value	0.01			1.00		

TABLE IV. Characteristics and Quantified Viral Load of HCV RNA in Plasma Which Was HCV RNA Negative by Cobas Amplicor HCV Version 2.0 (Sensitivity, 50 IU/ml)

Patients	Outcome	Sampling	HCV RNA (copies/ml)
1	Relapse	Week 4	3.5
2	Relapse	Week 4	8.0
3	Relapse	EOT	4.9
4	Relapse	EOT	11.0
5	Relapse	EOT	3.5
6	Relapse	EOT	17.3
7	SVR	Week 4	3.5
8	SVR	Week 4	7.6

EOT, End-of-treatment.

Several clinical studies have shown that early viral assessments provide identification of nonresponders to antiviral therapies [Davis et al., 2003; Jensen et al., 2006], and the consensus guidelines of American Association of Study for Liver Disease (AASLD) [Strader et al., 2004] recommended discontinuation of therapy in patients who do not achieve EVR. Moreover, Jensen et al. [2006] suggested that therapy can be discontinued by 24 weeks in patients who achieve rapid virologic response at week 4, because there was no significant difference in rate of sustained virologic response between patients treated for 24 and 48 weeks. However, virologic relapse occurs at various rates among patients with rapid virologic response (9–27%) [Jensen et al., 2006].

The ratios of sustained virologic response among patients who were HCV negative at week 4 of treatment by the present assay and COBAS Amplicor were 12/13 (92%) and 14/17 (82%), respectively, suggesting that undetectability of HCV RNA at week 4 by the more sensitive assay is more predictive of sustained virologic response. The threshold of plasma viral levels in patients with a strong virologic suppression during the early phase that leads to sustained virologic response may be much below 50 IU/ml. The qualitative transcription-mediated amplification assay, which has a higher sensitivity than COBAS Amplicor (detection limit 25–50 copies/ml), showed a slightly higher detection rate for HCV RNA than COBAS Amplicor (18/21 (86%) by transcription-mediated amplification assay versus 16/21 (76%) by COBAS Amplicor) in the testing of week-4 samples from relapsers [Desombere et al., 2005]. Because the sensitivity of the present RT-nested PCR assay is higher than that of the transcription-mediated amplification assay (5 copies/ml vs. 25–50 copies/ml at 95% detection), the predictability of sustained virologic response by the RT-nested PCR assay may be higher than by the transcription-mediated amplification assay.

Despite of the high sensitivity in detecting a single copy, one of nine samples at week four in relapsers was HCV-negative by the present assay. There are two possible explanations for this result. First, antiviral treatment leads to a complete replication arrest in blood, but small quantities of HCV RNA may persist in the liver [Radkowski et al., 2005]. Second, macrophages and lymphocytes may serve as a replication sites for HCV RNA, resulting in failure of detection of HCV RNA in plasma samples [Laskus et al., 2000; Watkins-Riedel et al., 2004; Radkowski et al., 2005]. On the other hand, detection of HCV RNA at week 4 is not well correlated with virologic relapse; 4 of 16 (25%) and 2 of 16 (13%) sustained virologic responders were HCV positive at week 4 by the present assay and COBAS Amplicor, respectively. It may be too early to identify patients with relapse or nonresponse by the detection of HCV RNA at week 4, because an early decision to discontinue treatment at week 4 would be a serious error in patients with the potential for a sustained virologic response.

In testing end-of-treatment samples, the RT-nested PCR assay detected residual HCV RNA in 4 of 12 (33%) relapsers, and 0 of 16 (0%) sustained virologic responders ($P = 0.02$), all of whom were HCV RNA negative by COBAS Amplicor. Despite of the small number of samples, this result suggests that patients who are HCV-positive by the RT-nested PCR assay at the end-of-treatment will relapse with quite a high probability after treatment. The detection rate of 33% in end-of-treatment samples from relapsing patients by the RT-nested PCR assay is similar to that obtained with the transcription-mediated amplification assay [Sarrazin et al., 2001; Desombere et al., 2005]. By retesting end-of-treatment samples with both the RT-nested PCR assay and the transcription-mediated amplification assay, it was found that the more highly sensitive assays can detect residual HCV RNA at the end-of-treatment from relapsers more frequently, and is suggested that virologic relapse occurs on the basis of replication of remaining HCV virions from a very low level after discontinuation of the antiviral therapy.

As previously reported, the level from which strongly suppressed HCV RNA can lead to virologic relapse is thought to be below 50 IU/ml, which may cause errors in the assessment of the efficacy of antiviral therapies [Sarrazin et al., 2001]. Indeed, the transcription-mediated amplification assay detected residual HCV RNA in the Amplicor-negative plasma from relapsers [Morishima et al., 2006]. However, there has been no report to quantify the minimum level of residual HCV RNA before virologic relapse. This study showed that the quantified HCV RNA concentration of relapsers was in the range of 3.5–17.3 copies/ml (Table IV), which is below the detection limit of the transcription-mediated amplification assay as well as that of the COBAS Amplicor HCV assay.

The assay had several limitations in its data and procedures. First, this study enrolled a limited number of patients. Particularly, the number of week-4 samples from relapsers ($n = 9$) was too small to evaluate the statistical difference in the detection rates between the present RT-nested PCR assay and the COBAS Amplicor HCV assay. Second, in comparison with commercially available kits, RT-nested PCR is labor-intensive, and thus is difficult to use for a large number of samples simultaneously. Therefore, the present assay may not be

suitable for routine use in clinical trials. However, since the threshold level of residual HCV RNA capable of producing a virologic relapse is quite low, the present assay may be useful for distinguishing virologic relapse from sustained virologic response.

In conclusion, a highly sensitive assay, almost capable of detecting a single copy of HCV RNA, was developed for the accurate prediction of the efficacy of antiviral therapy in HCV infection. It has been shown that sustained virologic response can be predicted by the undetectablity of HCV RNA at week 4, and, more strongly, that relapse is associated with detection of HCV RNA at the end-of-treatment.

REFERENCES

Cohen J. 1999. The scientific challenge of hepatitis C virus. Science 285:26–30.

Davis GL, Wong JB, McHutchinson JG, Manns MP, Harvey J, Albrecht J. 2003. Early Virologic response to treatment with peginterferon alfa-2b plus ribavirin in patinets with chronic Hepatitis C. Hepatology 38:645–652.

Desombere I, Vlierberghe HV, Couvent S, Clinckspoor F, Leroux-Roels G. 2005. Comparison of Qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and Quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) Assays for Hepatitis C Virus (HCV) RNA Detection and Qualification: Impact on Diagnosis and Treatment of HCV Infections. J Clin Microbiol 43: 2590–2597.

European Association for the Study of the Liver. 1999. EASL International Consensus Conference on Hepatitis C. Paris, 26–28, February 1999, consensus statement. J Hepatol 30:956–961.

Fried MW, Shiffman ML, Reddy R, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982.

Gerotto M, Pero FD, Bortoletto G, Ferrari A, Pistis R, Sebastiani G, Fagiuoli S, realdon S, Alberti A. 2006. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 40: 83–87.

Gorrin G, Friesenhahn M, Lin P, Sanders M, Pollner R, Eguchi B, Pham J, Roma G, Spidle J, Nicl S, Wong C, Bhade S, Comanor L. 2003. Performance evaluation of the VERSANT HCV RNA qualitative assay by using transcription mediated amplification. J Clin Microbiol 41:310–317.

Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bemstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, for the PEGASYS International Study Group. 2004. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355.

Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy R, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B. 2006. Early Identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 43:954–960.

Laskus T, Radkowski M, Piasek A, Nowicki M, Horban A, Cianciara J, Rakela J. 2000. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes. J Infect Dis 181:442–448.

Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK, International Hepatitis Interventional Therapy Group. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 358:958–965.

Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR, the HALT-C Trial Group. 2006. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis. Hepatology 44:360–367.

National Institutes of Health Consensus Development Conference. 2002. Statement: Management of hepatitis C. Hepatology 36:S3–S20.

Puig M, Mihalik K, Yu MW, Feinstone SM, Major ME. 2002. Sensitivity and reproducibility of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay. J Virol Method 105:253–263.

Radkowski M, Gallegos-Orozco JF, Jablonska J, Colby TV, Walewska-Zielecka B, KUbicka J, Wilkinson J, Adair D, Rakela J, Laskus T. 2005. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005. 41:106–114.

Saldanha J, Lelie N, Heath A, the WHO Collaborative Study Group. 1999. Establishment of the first international standard for nucleic acid amplification technoloby (NAT) assays for HCV RNA. Vox Sang 76:149–158.

Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. 2001. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatits C virus treated with peginterferon α-2a. J Clin Microbiol 39:2850–2855.

Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Leigh Brown AJ. 1990. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 64:864–872.

Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. 2004. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171.

Torriani FJ, Todriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, for the APRICOT Study Group. 2004. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-infected Patients. N Eng J Med 351:438–450.

Watkins-Riedel T, Ferenci P, Steidl-Munda P, Gschwantler M, Mueller C, Woegerbauer M. 2004. Early prediction of hepatitis C virus (HCV) infection relapse in nonresponders to primary interferon therapy by means of HCV RNA whole-blood analysis. Clin Infect Dis 39:1754–1760.

Young KKY, Resnick RM, Myers TW. 1993. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 31:882–886.

Ann. Cancer Res. Therap. Vol. 16, No. 1, pp. 8-11, 2008

Original Article

Individual tissue culture system in a disposable capsule with hypoxic atmosphere

Satoru Kaneko[1], Kiyoshi Takamatsu[1], Joji Yoshida[1], Keisuke Miyaji[2], Hiromichi Ishikawa[2], Toru Kawamata[3], Naoshi Shinozaki[4]

[1]*Reproduction Center (Gynecology), Tokyo Dental College Ichikawa General Hospital,*
[2]*Reproduction Center (Urology), Tokyo Dental College Ichikawa General Hospital,*
[3]*Airtech Japan, Ltd.,* [4]*Cornea Center, Tokyo Dental College Ichikawa General Hospital*

Abstract

In the present study, a novel system for the hypoxic culture of individual tissues was established for the subculturing of cell lines for research as well as for clinical culture of primary cells. To provide a hypoxic environment throughout the process of tissue handling and culture, we designed a clean bench with CO_2 gas circulation and a hypoxic culture incubator containing disposable capsules. The bench top was covered with an acrylic chamber, and an atmosphere of 5.0% CO_2-air was maintained using a sensor control. The cleanliness class of the chamber could easily be improved to 1 within 5 min of circulative filtration, even though it was found to be 10^5 before the unit was operated. Gas buffer solution (220 ml of 20 mM HEPES, 25 mM $NaHCO_3$, pH 7.4) placed in a 500-ml plastic capsule in the unit stabilized the culture environment by functioning as a heat storage and gas pool. The inflow of air that occurred by the cap of the capsule was opened was excluded by the infusion of purging gas (5.0% CO_2 and 95% N_2); the O_2 level returned to 2.0% within 4 min, after which the gas supply automatically switched to the culture gas (2.0% O_2, 5.0% CO_2, and 93% N_2). If this purging process was omitted, restoration of the O_2 level required 120 min, even though the inner volume was only 280 ml.

Keywords: individual tissue culture, gas circulation clean bench, hypoxic culture, disposable capsule

(Received January 31, 2008; Accepted February 4, 2008)

Introduction

Tissue culture plays an important role in cell biology, and it is mainly focused towards the subculturing of established cell lines. Culture equipments such as the clean bench and CO_2 incubator have been widely employed, and they provide the appropriate settings for the handling of tissues by supplying filtered fresh air and an atmosphere with saturated humidity and 5.0% CO_2, respectively. It is well known that the oxygen tension in the periphery is substantially lower than that of fresh air. Only some mutant variants that tolerate the given culture conditions such as the atmosphere and culture medium can adapt to long-term subculturing. Although media compositions have been discussed in detail, few efforts have been channeled towards ensuring that the oxygen tension at the original growth environments remains unchanged. The development of a hypoxic culture system will enable the subculturing of many more malignant tissues than what is currently possible. Recent advances in regenerative medicine require the culturing of primary cells or stem cells, and advances with regard to transplantation in humans demand more precise duplication of the original growth environments. Recent reports have indicated the influence of hypoxic culture on some cellular functions. BeWo cells - an in vitro model of human trophoblasts - were cultured in 2% O_2, and RT-PCR conducted after the culture indicated that transcription of the organic cation transporter OCTN2 was higher than that after culture in 20% O_2[1]. Hirao et al.[2] observed that when MC3T3-E1 cells and calvariae from 4-day-old mice were cultured in conditions of 20% or 5% O_2, osteoblastic differentiation and the subsequent transformation to osteocytes were promoted by low oxygen tension.

Some structures and mechanisms of conventional culture equipments are not designed to maintain low oxygen tension in the environment when tissues are being handled and cultured. The present study established a new hypoxic tissue culture system for the culturing of cell lines and primary cells in research and clinical settings, respectively.

Materials and Methods

Measurements with regard to particles in air: The degree of air cleanliness was defined in terms of "cleanliness classes" that are specified by the number of particles of size 0.5 μm or more in 1 cubic foot of air[3]. For in-

Correspondence to: Dr. Satoru Kaneko, Reproduction Center (Gynecology), Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa-shi, Chiba 272-8513 Japan. E-mail: kaneko@tdc.ac.jp, Tel (+81) 47-322-0151

stance, cleanliness class 100 indicates less than 100 particles of the specified size in 1 cubic foot of air. Particle size and number were simultaneously measured using a light-scattering particle counter (KC-03A, Rion, Tokyo, Japan). When an intake air stream is passed through a high-intensity laser beam, the particles in the stream scatter light. The particle sizes were divided across 5 categories in terms of the particle diameter (0.3–0.5 μm, 0.5–1.0 μm, 1.0–2.0 μm, 2.0–5.0 μm, and >5.0 μm), and the number of particles belonging to each category was assessed.

Measurement of temperature and O_2 concentration: The temperature sensor in the device (K470; Techno-Seven, Tokyo, Japan) had a resolution of ± 0.02°C. The O_2 concentration was measured using a galvanic current sensor.

Preparation of premixed gas and accuracy control: In the present study, we used commercially supplied premixed gases for culture (2.0% O_2, 5.0% CO_2, and 93% N_2) and for purging the capsules (5.0% CO_2 and 95% N_2). Pure O_2, CO_2, and N_2 gases were mixed according to their weights of corresponding molar ratios and filled in a container; in a pre-shipment review, their composition was assessed using gas chromatography. Post-receipt accuracy control was performed as follows: when the gases were aerated in a solution containing 20 mM HEPES, 25 mM $NaHCO_3$ at 37°C, and the composition was considered accurate if the pH of the solution remained at 7.4 ± 0.05 after gas equilibration.

Results

1. Clean bench with CO_2 gas circulation

In the present study, a new clean bench with CO_2 gas circulation and a built-in microscope was developed. As shown in Fig. 1, the bench top was covered with an acrylic chamber to prevent leakage of the ambient atmosphere; it resembled an infant incubator. Pure CO_2 was infused using a gas sensor control to maintain the composition at 5.0% CO_2-air, and the temperature was maintained at 30–37°C by using a temperature control (Fig. 2). In addition, if the tissue did not allow exposure to 5.0% CO_2-air, the culture dish was isolated in a small chamber placed on the bench top, and humidified culture gas was supplied to it. While fresh air is filtered only once in the conventional clean bench, the enclosed 5.0% CO_2-air was circulated through HEPA filter every 24 s in the present system. As shown in Fig. 3, the cleanliness class of the air was found to be approximately 4×10^5 before operation of the unit was initiated; particles larger than 0.5 μm were not found, and only 10 particles of size 0.3–0.5 μm were observed in 1 cubic foot of air after 5 min of operation. Repeated filtration easily yielded cleanliness class 1. Thus far, if bench tops were contaminated by some infectious material such as body fluid, they were merely wiped clean. In the present system, however, a disposable clear film is placed as a covering shield on the bench top, and it is discarded after each operation.

2. Hypoxic culture of individual tissues in disposable capsules

We developed a disposable capsule for hypoxic tissue culture (Fig. 4). A 500-ml plastic capsule containing 220 ml of the gas buffer solution (20 mM HEPES, 25 mM $NaHCO_3$) was used; it functioned as a heat storage as well as a gas pool. The culture bath had a 16-well aluminum block for heat storage, and the block and the inner space were maintained at 37°C by using a temperature sensor (Fig. 5). First, the gas buffer solution was equilibrated by infusion of a small amount of the culture gas (10 ml/min) at least overnight. When the door was opened for 10 s, a slight temperature change of 0.1°C was observed in the inner space of the capsule, and it was restored within 7 min.

When conducting tissue culture using this capsule, the inflow of air when the cap is opened should be excluded as soon as possible; The purging gas was flushed (500 ml/min) immediately after the cap was closed, and the O_2 level was restored to 2.0% within 4 min; the gas supply automatically switched to the culture gas, which was continuously infused (10 ml/min) to maintain positive pressure (Fig. 6). If this process was omitted, the restoration of the O_2 level required 120 min, even though the inner volume was only 280 ml. In this system, gas control with a CO_2 sensor was unnecessary, and improper control due to the sensor deterioration was not required to be considered. Gas equilibration in each capsule was roughly estimated by the color of phenol red in the gas buffer solution, and the precise control of the culture environments were monitored by measuring the temperature and pH of the gas buffer solution. Although simultaneous culturing of multiple tissues in a single CO_2 incubator is usually possible, the present method that facilitates the culturing of individual tissues in disposable capsules has some advantages: the individual dish can be easily identified without any confusion, and the culture conditions are not disturbed when the door of the unit is opened.

Discussion

The cleanliness class of room air is generally 10^6–10^5. A low-dust environment with a cleanliness class of 10^2 would be provided when the conventional clean bench is operated under the optimum conditions. However, tissues are handled in fresh air, and under these conditions, O_2 may be dissolved in the medium, and the pH could change due to CO_2 removal. The present clean bench with CO_2-air circulation had overcome the above defects, and the functions had been rather similar with the conventional CO_2 incubator.

Fig. 1 Clean bench with CO_2 gas circulation



Fig. 2 Temperature of the clean bench
A: fresh air, B: ambient atmosphere, C: bench top



Fig. 3 Change in cleanliness class after beginning of operation
The values are represented as mean ± standard error. They were measured at 5 points on the bench.

Fig. 4 Disposable capsules for hypoxic tissue culture
A maximum of 5 culture dishes (6.0-cm diameter) can be placed on the tray on the stainless steel stand. The gas buffer solution is placed at the bottom of the stand. The 2 tubes protruding from the cap are the gas inlet and outlet.



Fig. 5 Culture bath with a 16-well aluminum block



Fig. 6 Effect of gas purging on the restoration of the O_2 level after the cap is closed
A: purging with 5.0% CO_2 and 95% N_2, B: no purging, but 10 ml/min supply of 2.0% O_2, 5.0% CO_2, and 93% N_2. The arrow indicates gas switching.

The conventional CO_2 incubator poses a structural problem if hypoxic tissue culture is to be performed. The inflow of fresh air cannot be avoided when the door is opened. The concentration of CO_2 can be restored by infusing pure CO_2 gas. As shown in Fig. 6, it is very difficult to remove O_2 once it enters the chamber, and the tissues may be exposed to a high concentration of O_2. It is well known that the partial pressure of O_2 in fresh air (159 mmHg) is reduced to 100 and 25 mmHg or less, respectively, in arterial blood and at the periphery. When the saturated vapor pressure at 37°C was estimated to be 47 mmHg, those in 5.0% CO_2-air and the culture gas were calculated to be 142 and 14.3 mmHg, respectively. Numerous authors have shown that reactive oxygen species (ROS) exert various harmful effects such as lipid and protein peroxidation and membrane and DNA damage[4-7], however, only a few reports have addressed the effects of O_2 tension in culture environments[1,2,8]. Tissues and cells in body fluids are protected from O_2 and ROS by physiological antioxidants that are limited in artificial culture media, and an extremely high level of O_2 promotes ROS generation. Since the tolerance of cells to O_2 and ROS differs, the optimum O_2 concentration should be established for each cell line in order to minimize cellular damages and subsequent mutation. In the present system, by changing the composition of the premixed gas, the concentration of O_2 can easily be set, in the range of 0%–95%.

Acknowledgement

This work was supported by Health and Labor Sciences Research Grants on Tissue Engineering (H17-022) from the Japanese Ministry of Health, Labor and Welfare.

References

1) Rytting, E., Audus, K.L. (2007) Effects of low oxygen levels on the expression and function of transporter OCTN2 in BeWo cells. J. Pharm. Pharmacol. 59: 1095-1102.
2) Hirao, M., Hashimoto, J., Yamasaki, N., Ando, W., Tsuboi, H., Myoui, A., Yoshikawa, H. (2007) Oxygen tension is an important mediator of the transformation of osteoblasts to osteocytes. J. Bone Miner. Metab. 25: 266-276.
3) JIS Z 8122: 2000 Contamination Control-Terminology
4) Yamamoto, Y., Niki, E., Kamiya, Y., Shimasaki, H. (1984) Oxidation of lipids. Oxidation of phosphatidyl cholines in homogeneous solution and in water dispersion. Biochim. Biophys. Acta, 795: 332-340.
5) Papa, S. (1984) Mitochondrial oxidative phosphorylation changes in the life span. Molecular aspects and physiopathological implications. Biochim. Biophys. Acta 1276: 87-105.
6) Bongarzone, E.R., Pasquini, J.M., Soto, E.F. (1995) Oxidative damage to proteins and lipids of CNS myelin produced by in vitro generated reactive oxygen species. J. Neurosci. Res. 41: 213-221.
7) Burhans, W.C., Weinberger, M. (2007) DNA replication stress, genome instability and aging. Nucleic Acid Res. 35: 7545-7556.
8) Balin, A.K., Goodman, D.B.P., Rasmussen, H., Cristofalo, V.J. (1978) The effect of oxygen tension on the growth and metabolism of WI-38 cells. J. Cell Physiol. 89: 235-250.

Studies on the Compatibility of HLA-Class II Alleles in Patient Couples with Severe Pre-Eclampsia Using PCR–RFLP Methods

Izumi Ooki, Koichi Takakuwa, Mami Akashi, Taro Nonaka, Tomokazu Yokoo, Kenichi Tanaka

Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata, Japan

Keywords

Compatibility, genotype, gestational hypertension, HLA-class II, PCR–RFLP, pre-eclampsia

Correspondence

Koichi Takakuwa, Department of Obstetrics and Gynecology, 1-757 Asahimachi-dori, Niigata 951-8510, Japan.
E-mail: obgy@med.niigata-u.ac.jp

Submitted January 11, 2008,
accepted February 11, 2008.

Citation

Ooki I, Takakuwa K, Akashi M, Nonaka T, Yokoo T, Tanaka K. Studies on the compatibility of HLA-class II alleles in patient couples with severe pre-eclampsia using PCR–RFLP methods. Am J Reprod Immunol 2008; 60: 75–84

doi:10.1111/j.1600-0897.2008.00592.x

Problem

In this study, we investigated whether or not significant compatibility of human leukocyte antigen (HLA)-class II alleles exists between spouses with severe pre-eclampsia (PE) (including gestational hypertension, GH).

Method of study

The HLA-class II genotypes were determined using a polymerase chain reaction-restriction fragment length polymorphism method. The number of incompatible alleles in 57 patient couples with severe PE (including GH) were determined, and compared with that in 74 control couples.

Results

The number of patient couples and control couples with each number of mismatched alleles of the HLA-DR, -DQ, and -DP genotypes was as follows. The number of patient couples with zero, one, two, three, and four-allele mismatches was 41 (72.9%), and with five and six-allele mismatches was 16 (27.1%). On the other hand, the number of control couples with zero, one, two, three, and four-allele mismatches was 38 (51.4%), and with five and six-allele mismatches was 36 (48.6%). Thus, the number of patient couples with five and six-allele mismatches was significantly lower compared with that in control couples. The same result was obtained as regards the mismatched alleles of the HLA-DR, -DQ, and -DP phenotypes.

Conclusion

These findings suggest that significant compatibility of HLA-class II alleles between spouses is implicated in the genesis of PE (including GH).

Introduction

Pre-eclampsia (PE) (including gestational hypertension, GH) is a major cause of both maternal and perinatal morbidity and mortality, which is diagnosed by the onset of hypertension with or without proteinuria during the latter half of pregnancy. Although both the etiology and pathogenesis of PE/GH are poorly understood, aberrations in the immune response have been suggested as likely causes of pathologies associated with pregnancy in view of the diversity of immunologic responses in pregnant women.[1] It is thought that insufficient maternal recognition of fetal (paternal) antigens is deleterious for the immunologically successful maintenance of pregnancy, which might cause a range of reproductive failures such as sterility, recurrent fetal wastage, and PE/GH.[2–4] Genes

 © 2008 The Authors
Journal compilation © 2008 Blackwell Munksgaard

located within the major histocompatibility complex (MHC) have been shown to be associated with a variety of diseases, and have been proposed to regulate reproductive processes in animals and humans. The MHC of human beings, the human leukocyte antigen (HLA), is well known to be useful in examining the immunogenetic basis of some diseases.[5,6] Several studies have attempted to reveal the association between antigens of the HLA system and development of PE/GH;[7–11] especially, the materno-paternal compatibility or disparity of HLA antigens in PE/GH patient couples was investigated by several investigators, although the results were conflicting.[12–16] In this study, we analyzed the HLA-class II alleles, i.e., HLA-DRB1, -DQB1, and -DPB1 genotypes and phenotypes in patient couples with severe PE/GH and normal fertile couples using a polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) method to clarify whether or not there is any relationship between the materno-paternal HLA compatibility and severe PE/GH.

Materials and methods

Patients and Controls

The HLA-DRB1, -DQB1, and -DPB1 genotypes were analyzed in 57 patients with severe PE/GH and their partners after obtaining informed consent. PE/GH was diagnosed according to the clinical criteria defined by the 'International Society for the Study of Hypertension in Pregnancy' (ISSHP).[17] All patients had severe hypertension diagnosed according to the same criteria. Patients who were positive for antiphospholipid antibodies, such as anti-cardiolipin antibodies, anti-cardiolipin beta-2-glycoprotein I antibodies, and lupus anticoagulant, were excluded from the study. Of 57 patients, 38 were primiparous women, and 19 cases in them had experienced one delivery. Thirteen previous pregnancies in 19 cases with delivery had been complicated with severe PE/GH, and those of remaining six cases had not been complicated with PE/GH.

As a control, 74 women who had experienced at least two normal deliveries without PE/GH and their husbands were examined for the HLA-DRB1, -DQB1, and -DPB1 genotypes also after obtaining informed consent. All individuals were Japanese women. Internal review board approval was obtained before the commencement of the study.

Analyses of HLA-DRB1, HLA-DQB1, and HLA-DPB1 Genotypes

Analyses of HLA-DRB1, HLA-DQB1, and -DPB1 genotypes were performed using the PCR–RFLP method.[18–20] The primers used in this study are listed in Table I, and endonucleases are listed in Table II.

Genomic DNAs, extracted by phenol extraction of sodium dodecyl sulphate-lysed and proteinase K-treated peripheral lymphocytes from each individual, were amplified by the PCR procedure with 2.5 units of *Taq* DNA polymerase (Takara Co., Ltd, Kyoto, Japan). The reaction mixture, which contained 1 μmol/L each of the PCR 3′ and 5′ primers, 1 μg of genomic DNA, 10 μL of dNTP mixture (Takara Co. Ltd), a PCR reaction buffer (10 mmol/L Tris–HCl, 50 mmol/L KCl, 1.5 mmol/L $MgCl_2$), and distilled water, to make a total volume 100 μL in a 0.5-mL eppendorf tube, was covered with 50 μL of mineral oil to prevent evaporation and subjected to 30 cycles of 1 min for denaturing, 1 min for annealing, and 2 min for extension in an automated PCR thermal cycler (Thermal Cyclic Reactor; Toyobo Engineering Co., Tokyo, Japan).

For HLA-DRB1 typing, seven group-specific primers, DR1, DR2, DR4, DR7, DR9, DR10, and DRw52-associated (DR3, −5, −6, and −8) antigen specific primers, were used to obtain only the amplified product from the DRB1 gene (Table I). The DR7, −9, −10 alleles, which have no suballeles (DRB1*0701 and 0702 have the same nucleotide sequences in their β1 domain exons), were simply typified by the presence of amplified bands as DRB1*0701 or 0702, DRB1*0901, and DRB*1001 respectively.

For HLA-DQB1 typing, a 241 base pair fragment from the second exon of the HLA-DQB1 gene was amplified using 1 μmol/L each of the PCR primers GH28NL + QB202 (DQ1 group specific primers), and a 237 base pair fragment was amplified using 1 μmol/L each of the PCR primers GH28NL + QB204 (DQ2,3,4 group specific primers).

For HLA-DPB1 typing, a 299 base pair fragment from the second exon of the HLA-DPB1 gene was amplified by using 1 μmol/L each of the PCR primers DPB101N and DPB201.

After amplification, aliquots (6 μL) of the reaction mixture, with an appropriate restriction buffer and restriction enzymes, were incubated for 1–3 hr.

*Ava*II and *Pst*I were used for digestion of the amplified DR1-DRB1, *Fok*I, *Cfr*13I and *Hph*I for

 © 2008 The Authors
Journal compilation © 2008 Blackwell Munksgaard

Table I PCR Primers for Amplification of the DRB1, DQB1, DPB1 Genes

Gene	Primer	Sequences (5' to 3')	Den	Ann	Ext
DRB1 for DR2	5' Primer 5'R2	TTCCTGTGGCAGCCTAAGAGG (261 bp)	94°C	60°C	72°C
DRB1 for DR4	5' Primer 5'R4	GTTTCTTGGAGCAGGTTAAAC (263 bp)	94°C	60°C	72°C
DRB1 for DR1	5' Primer 5'R1	GGTTGCTGGAAAGATGCATCT (206 bp)	94°C	55°C	72°C
DRB1 for DR7	5' Primer 5'R7	AGTTCCTGGAAAGACTCTTCT (206 bp)	94°C	60°C	72°C
DRB1 for DR10	5' Primer 5'R10	GGTTGCTGGAAAGACGCGTCC (206 bp)	94°C	60°C	72°C
DRB1 for DR3	5' Primer 5'R3568	ACGTTTCTTGGAGTACTCTACG (265 bp)	94°C	60°C	72°C
DR5					
DR6					
DR8					
	3' Primer 3'R[a]	CCGCTGCACTGTGAAGCTCT			
DRB1 for DR9	5' Primer 5'R9	GGACGGAGCGGGTGCGGTATC (193 bp)	94°C	63°C	72°C
	3' Primer 3'R9	CCGTAGTTGTGTCTGCACACGG			
DQB1 for DQ1	5' Primer GH28NL	GCATGTGCTACTTCACCAACG (241 bp)	94°C	55°C	72°C
	3' Primer QB202	CACCTGCAGATCCCGCGGTACGCCACCTC			
DQB1 for DQ2	5' Primer GH28NL	GCATGTGCTACTTCACCAACG (237 bp)	94°C	55°C	72°C
DQ3	3' Primer QB204	CACCTGCAGTGCGGAGCTCCAACTGGTA			
DQ4					
DPB1	5' Primer DPB101N	GTGAAGCTTTCCCCGCAGAGAATTAC (299 bp)	94°C	62°C	72°C
	3' Primer DPB201	CACCTGCAGTCACTCACCTCGGCGCTG			

Den = denaturing; Ann=annealing; Ext = extension.
[a]Common for DRB1 alleles except the DR9 allele.
The time of denaturing is 1 min, that of annealing is 1 min and that of extension is 2 min.

Table II Restriction Endonucleases for Genotyping of DRB1, DQB1 and DPB1 Alleles

Allele	Antigen	Restriction endonuclease
DRB1	DR1	*AvaII*, *PstI*
	DR2	*FokI*, *Cfr13I*, *HphI*
	DR3,5,6,8	*AvaII*, *FokI*, *KpnI*, *HaeII*, *Cfr13I*, *SfaNI*, *SacII*, *BsaJI*, *ApaI*, *HphI*, *RsaI*
	DR4	*SacII*, *AvaII*, *HinfI*, *HaeII*, *HphI*, *MnlI*
DQB1	DQw1	*FokI*, *ApaI*, *HaeII*, *SfaNI*, *BssHII*, *HphI*
	DQw2,3,4	*FokI*, *BglI*, *SacI*, *AcyI*, *HpaII*
DPB1		*Bsp1286I*, *FokI*, *DdeI*, *BsaJI*, *BssHII*, *Cfr12I*, *RsaI*, *EcoNI*, *AvaII*

DR2-DRB1, *SacII*, *AvaII*, *HinfI*, *HaeII*, *HphI* and *MnlI* for DR4-DRB1, *AvaII*, *FokI*, *KpnI*, *HaeII*, *Cfr13I*, *SfaNI*, *SacII*, *BsaJI*, *ApaI*, *HphI* and *RsaI* for DR3,5,6 and 8-DRB1.

FokI, *ApaI*, *HaeII*, *SfaNI*, *BssHII*, *HphI*, were used to digest the amplified DQB1 genes with DQ1, and *FokI*, *BglI*, *SacI*, *AcyI*, *HpaII* were used to digest the amplified DQB1 genes with DQ2,3, and 4 (Table II).

Bsp1286I, *FokI*, *DdeI*, *BsaJI*, *BssHII*, *Cfr13I*, *RsaI*, *EcoNI*, and *AvaII* were used to perform single digestion of the amplified DPB1 genes (Table II).

Samples of the amplified DNAs cleaved by restriction enzymes were subjected to electrophoresis using a 12% polyacrylamide horizontal gel in a minigel apparatus (AE-6450; Atto Corporation, Tokyo, Japan). Cleavage or no cleavage of amplified fragments was detected by staining with ethidium bromide.

Human leukocyte antigen-DRB1 genotypes were determined by comparing the restriction fragment patterns to those of amplified DRB1 genes reported by Ota et al.,[18] and HLA-DQB1 genotypes were determined by comparing the patterns with those of amplified DQB1 genes reported by Nomura et al.[19] HLA-DPB1 genotypes were determined by comparing the patterns of restriction fragment polymorphism obtained in tested individuals with those of the amplified DPB1 gene reported by Ota et al.[20]

Scoring of the Number of Mismatched Alleles

A two-alleles mismatch was scored when both of the paternal alleles at one locus were different from

Table III List of HLA Class II Alleles in Patients and Their Husbands

No. of patient	Wife or husband	Age of patient	Pre-eclampsia or gestational hypertension	HLA-DRB1	HLA-DQB1	HLA-DPB1
1	Wife	28	PE	0803/1201	0303/0601	0501/0501
	Husband			0901/1302	0303/0604	0201/0401
2	Wife	31	PE	0901/1201	0302/0303	0201/0501
	Husband			0901/0901	0303/0303	0201/0301
3	Wife	32	PE	0405/0803	0401/0601	0201/0501
	Husband			0405/1302	0401/0604	0401/0501
4	Wife	27	GH	0101/0402	0303/0501	0501/1801
	Husband			0405/1302	0303/0401	0501/0501
5	Wife	27	PE	0410/1501	0402/0602 = 03	0201/0301
	Husband			0101/1501	0501/0602 = 03	0202/1601
6	Wife	38	PE	1401/1502	0503/0601	0901/1401
	Husband			1301/1502	0601/0602 = 03	0201/1701
7	Wife	25	PE	0101/0406	0302/0501	0201/0501
	Husband			0405/1301	0401/0602 = 03	0201/0501
8	Wife	28	PE	1201/1401	0301/0502	0201/0501
	Husband			0803/1302	0601/0602 = 03	0201/0501
9	Wife	31	PE	0403/1302	0302/0604	0201/0401
	Husband			0405/0803	0401/0601	0201/0501
10	Wife	25	PE	0901/1501	0303/0602 = 03	0501/1301
	Husband			1201/1501	0301/0602 = 03	0401/1001
11	Wife	21	GH	0405/0406	0302/0401	0501/0501
	Husband			1401/1401	0302/0601	0201/0301
12	Wife	30	PE	0403/0405	0302/0401	0501/0501
	Husband			0403/0410	0303/0303	0201/0301
13	Wife	28	PE	1202/1502	0301/0601	0501/0901
	Husband			0901/0901	0303/0303	0501/0501
14	Wife	36	GH	0803/1302	0601/0604	0202/0401
	Husband			0101/0405	0401/0501	0201/0201
15	Wife	38	PE	1201/1502	0301/0601	0501/0901
	Husband			1201/1501	0303/0602 = 03	0201/0501
16	Wife	37	PE	0101/0802	0302/0501	0201/0501
	Husband			0901/1502	0303/0601	0501/1701
17	Wife	27	PE	0803/0803	0302/0502	0201/0501
	Husband			1501/1501	0601/0602 = 03	0501/1701
18	Wife	21	PE	1101/1405	0301/0503	0201/0501
	Husband			1401/1502	0502/0601	0402/1701
19	Wife	33	PE	0405/1201	0303/0401	0301/0402
	Husband			1501/1602	0502/0602 = 03	0501/0501
20	Wife	31	GH	1501/1501	0602 = 03/0602 = 03	0402/1301
	Husband			0406/0901	0302/0303	0501/1401
21	Wife	20	PE	1201/1502	0301/0601	0501/1701
	Husband			0101/1201	0301/0501	0402/0501
22	Wife	34	PE	1302/1502	0601/0604	0401/1701
	Husband			1501/1602	0602 = 03/0602 = 03	0501/0501
23	Wife	27	PE	0406/1401	0302/0503	0201/0501
	Husband			0101/0407	0302/0601	0501/1701
24	Wife	26	PE	0403/1101	0302/0302	0501/0501
	Husband			0901/1405	0302/0503	0501/0501
25	Wife	37	PE	0405/1502	0401/0601	0201/0501
	Husband			0802/1401	0302/0502	0501/0501

Table III (Continued)

No. of patient	Wife or husband	Age of patient	Pre-eclampsia or gestational hypertension	HLA-DRB1	HLA-DQB1	HLA-DPB1
26	Wife	25	PE	0405/1502	0401/0602 – 03	0501/0501
	Husband			0803/1502	0601/0601	0501/1701
27	Wife	27	PE	1201/1201	0303/0501	0501/0501
	Husband			0403/1502	0302/0601	0301/0901
28	Wife	23	PE	0405/1201	0303/0401	0501/0501
	Husband			0804/1101	0301/0302	0402/0501
29	Wife	27	PE	0803/1201	0303/0601	0201/0501
	Husband			0901/1502	0402/0601	0201/1701
30	Wife	34	PE	0405/1405	0401/0503	0402/0501
	Husband			0405/1502	0401/0601	0201/0201
31	Wife	34	PE	0901/0901	0303/0502	0201/0501
	Husband			0403/1302	0302/0604	0201/0201
32	Wife	28	PE	0405/0802	0401/0402	0202/0501
	Husband			0405/0406	0302/0401	0402/0501
33	Wife	23	PE	1401/1405	0502/0503	0501/1401
	Husband			1202/1501	0301/0604	0501/0501
34	Wife	25	PE	0405/1302	0401/0604	0501/0501
	Husband			0403/0405	0302/0401	0402/0501
35	Wife	43	PE	0405/0802	0302/0401	0501/0501
	Husband			0403/0901	0302/0303	0301/0501
36	Wife	24	PE	0901/1401	0303/0502	0402/0501
	Husband			0803/0901	0303/0601	0201/0501
37	Wife	29	PE	0901/1502	0303/0602 – 03	0301/0402
	Husband			0405/0408	0302/0401	0402/0501
38	Wife	42	PE	0405/1501	0401/0602 – 03	0501/0501
	Husband			0403/0406	0302/0302	0201/0201
39	Wife	27	PE	0405/1501	0402/0602 – 03	0201/0501
	Husband			0408/1501	0301/0602	0201/1401
40	Wife	35	GH	1302/1302	0303/0604	0401/0402
	Husband			0803/0803	0303/0601	0201/0202
41	Wife	33	GH	0410/1501	0402/0602 – 03	0201/0401
	Husband			0407/0901	0302/0303	0201/0301
42	Wife	32	GH	1001/1502	0501/0601	0201/1701
	Husband			0406/0901	0303/0402	0501/0501
43	Wife	32	PE	0410/0803	0402/0601	0201/0402
	Husband			0405/1502	0401/0601	0201/1701
44	Wife	33	PE	0901/1501	0303/0602 – 03	0201/0501
	Husband			1201/1403	0301/0604	0201/0401
45	Wife	30	GH	0405/0901	0303/0401	0201/0202
	Husband			0405/0901	0303/0401	0201/0501
46	Wife	33	PE	0405/1201	0303/0401	0501/0501
	Husband			0901/1502	0303/0601	0201/0501
47	Wife	31	PE	1302/1501	0604/0604	0201/0402
	Husband			1201/1302	0303/0604	0401/0501
48	Wife	31	PE	0405/1405	0401/0503	0501/0501
	Husband			0403/1101	0301/0302	0201/0501
49	Wife	30	GH	0101/1302	0501/0602 – 03	0201/0501
	Husband			1403/1502	0301/0601	0201/1701
50	Wife	39	PE	0406/0803	0302/0601	0201/0501
	Husband			0407/1405	0302/0503	0201/0501

Table III (Continued)

No. of patient	Wife or husband	Age of patient	Pre-eclampsia or gestational hypertension	HLA-DRB1	HLA-DQB1	HLA-DPB1
51	Wife	35	PE	0901/0901	0303/0303	0201/0501
	Husband			0403/1502	0302/0601	0201/0501
52	Wife	30	PE	0410/1101	0302/0402	0301/0501
	Husband			1302/1501	0602/0604	0201/0201
53	Wife	25	PE	0403/1502	0402/0601	0201/0901
	Husband			0403/0802	0302/0302	0201/0201
54	Wife	32	PE	0101/1501	0501/0601	0401/1701
	Husband			1502/1502	0302/0601	0201/0901
55	Wife	35	PE	0405/0405	0401/0401	0301/0501
	Husband			0901/1302	0402/0402	0401/0501
56	Wife	34	PE	0405/0901	0303/0401	0201/0501
	Husband			0401/1201	0302/0401	0201/0501
57	Wife	26	PE	0405/0803	0401/0601	0501/1801
	Husband			1501/1501	0303/0303	0501/0501

their partner's types for the HLA-DRB1 genotypes or phenotypes, HLA-DQB1 genotypes or phenotypes, and HLA-DPB1 genotypes or phenotypes, respectively. If one allele was shared, one mismatch was scored. If genotypes or phenotypes from both individuals were identical, a zero mismatch was recorded. A zero mismatch was also recorded in cases where the male was homozygous for a genotype or phenotype shared by his partner. Thus, the number of mismatched types of one locus ranged from zero to two, and the number of mismatched types of three loci (HLA-DRB1 genotypes or phenotypes, HLA-DQB1 genotypes or phenotypes, and HLA-DPB1 genotypes or phenotypes) ranged from zero to six.

Statistical Analyses

The chi-squared test was used to analyze any significance in the difference between the number of incompatible alleles for the HLA-DRB1 genotypes or phenotypes, HLA-DQB1 genotypes or phenotypes, and HLA-DPB1 genotypes or phenotypes in the patient and control couples.

Results

A list showing the HLA-genotyping of the patients with severe PE/GH and their partners is shown in Table III. The age of the patients ranged from 20 to 43 years. Of 57 patients, nine cases had only GH, and the remaining 48 cases had hypertension with proteinuria (PE).

The numbers of patient couples and control couples with each number of mismatched alleles of the HLA-DR genotype and phenotype are shown in Table IV. Of 57 patient couples, a two allele-mismatch of the HLA-DR genotype was observed in 34 couples (59.7%), and a one allele-mismatch was observed in 21 couples (36.8%), while no mismatch was observed in two couples (3.5%). Of 74 control

Table IV Number of Incompatible Alleles of HLA-DR Genotype and Phenotype in Patient Couples with PE/GH and Control Couples

The number of incompatible alleles	Incompatible allele DR genotype The number of couples		Incompatible allele DR phenotype The number of couples	
	Patients ($n = 57$)	Controls ($n = 74$)	Patients ($n = 57$)	Controls ($n = 74$)
0	2 (3.5)	3 (4.1)	9 (15.8)	8 (10.8)
1	21 (36.8)	20 (27.0)	28 (49.1)	28 (37.8)
2	34 (59.7)	51 (68.9)	20 (35.1)	38 (51.4)

Values in parentheses are expressed as percentage.
Not significant by chi-squared test.